physiciansweekly.com
Genetic Susceptibility and Comorbidities in Psoriasis and HS
People with both psoriasis and hidradenitis suppurativa appear to have higher overall morbidity and a greater observed risk of Crohn’s disease. Genetic findings suggest shared biological pathways that could affect how these patients are understood and monitored.
Clinicians treating patients with psoriasis and/or hidradenitis suppurativa, researchers studying shared genetics of inflammatory diseases, and patients with both conditions or with interest in comorbidity risk.
What To Know
This article summarizes a retrospective study (JAAD) examining patients with both psoriasis (PSO) and hidradenitis suppurativa (HS).
The investigators used clinical and genetic data from an international cohort and found that people with both conditions (PSO‑SH) had higher overall morbidity and a higher observed risk of Crohn’s disease compared with those with only one condition.
Genetic risk scores (non‑HLA loci) were higher in the combined PSO‑SH group, suggesting shared genetic susceptibility. What this report seems to say: PSO and HS can co-occur and when they do, patients in this study had more comorbidities and a different genetic risk profile than those with only psoriasis or only HS.
The authors highlight a notably increased association with Crohn’s disease in the PSO‑SH group. How patients might use this: If you have psoriasis and HS together, this study suggests clinicians may consider monitoring for other inflammatory conditions (including Crohn’s disease) and recognizing that this subgroup may carry higher overall morbidity.
It does not report on changes to treatment or specific management steps. What it doesn’t show: This is a retrospective observational study; it identifies associations and genetic signal differences but does not prove causation or indicate new treatments.
This is a retrospective cohort analysis summarized from JAAD; findings are associative and based on genetic risk scores rather than causal proof. The article does not provide new treatment recommendations and further research is needed to translate genetic associations into clinical practice.
